BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Jennewein Biotechnologie GmbH and Pfizer Nutrition Collaborate on Human Milk Components


8/29/2011 10:37:06 AM

RHEINBREITBACH, Germany, August 29, 2011 /PRNewswire/ --

Jennewein Biotechnologie today announced that the company has signed a license agreement with Pfizer Nutrition to develop and market two Human Milk Oligosaccharides (HMOs).

Human Milk Oligosaccharides represent a major component of mother's milk, and provide short and long-term benefits to infants from birth onwards. Scientific research has shown that HMOs can significantly lower infants' risk of infection during the time of lactation. In addition, these compounds are known to influence colonization of beneficial bacteria and support healthy immune development.

The partnership will focus on enabling the functional and immunological benefits of HMOs to become available to infants being fed with infant formulas. Human milk, the "gold standard" due to its special composition of lipids, proteins and HMOs, is the best nutrition for infants.

"Building upon nearly a century as pioneers in infant nutritional science, we are constantly striving to more closely replicate the composition and functional benefits of breast milk, and this partnership truly helps further this mission," stated John Troup, PhD, Vice President, Global Research & Development, Pfizer Nutrition.

Dr. Stefan Jennewein, Managing Director and Cofounder of Jennewein Biotechnologie, underlines, "Complex oligosaccharides in general and HMOs in particular show an enormous potential for use in human nutrition. The cooperation between Pfizer Nutrition and Jennewein Biotechnologie will accelerate the developments in this field by bringing together specific complementary competencies."

Jennewein plans to also focus on adult nutrition, in addition to infant formulas, in the commercialization of HMOs so as to bring the benefits of this natural product to a broader group of consumers.

About Jennewein Biotechnologie

Jennewein Biotechnologie GmbH, found in 2005 in Rheinbreitbach (Germany), is a science based company in the field of industrial biotechnology. The company is focusing its activities on the development of innovative production processes for scarce and complex mono- and oligosaccharides. The mission of Jennewein Biotechnologie is to provide sugars with scientifically proven health benefits and to make these available to larger consumer groups.

About Pfizer Nutrition

Pfizer Nutrition, formerly Wyeth Nutrition, is part of Pfizer Inc. Pfizer Nutrition supports the company's mission to improve health and well-being at every stage of life, bringing breadth and depth of consumer and scientific insight to new populations and new markets around the world. Pfizer Nutrition brings together almost a century of experience in which the company has leveraged clinical rigor, scientific research, world class manufacturing and product safety standards to drive scientifically-sound solutions that offer parents confidence, help nourish children and support their healthy futures. We develop premium-quality nutritional products that are scientifically-designed to meet the needs of infants and young children, as well as pregnant and lactating mothers.

For Immediate Release
Media Inquiries:
Jennewein Biotechnologie GmbH
Amélie Jennewein
Maarweg 32
53619 Rheinbreitbach
Germany
Tel. +49(0)2224-967-9669
Fax. +49(0)2224-988-0854
Email: info@jennewein-biotech.de

http://www.jennewein-biotech.de


SOURCE Jennewein Biotechnologie GmbH



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->